Chlorthalidone

ABSTRACTFixed drug eruption (FDE) is one of the most common cutaneous adverse drug reactions in Indian patients. Chlorthalidone (CTD), a thiazide-type diuretic that inhibits distal convoluted tubule sodium and chloride resorption, is a commonly used oral antihypertensive. We are presenting a case of chlorthalidone induced FDE where a 75 year old hypertensive male admitted in hospital with complains of rashes associated with burning sensation on trunk, back and left arm after the administration of tablet chlorthalidone. FDE is believed to be a lymphocyte CD8-mediated reaction, wherein the offending drug may induce local reactivation of memory T cell lymphocytes localized in epidermal and dermal tissues and targeted initially by the viral infection. The initial treatment of FDE is discontinuation of the causative agent. Keywords: Fixed drug eruption, Chlorthalidone, Cutaneous adverse drug reactions

A sensitive and reproducible RP-HPLC method was described for the quantitative determination of chlorthalidone and olmesartan in combined dosage form. This method was based on high performance liquid chromatographic (HPLC) separation of chlorthalidone and olmesartan with the use of a reversed phase HPLC column [Hypersil BDS, C18, 100 x 4.6 mm, 5m] at mobile phase consisting of phosphate buffer (pH-3.3) and acetonitrile in the ratio of 55:45 v/v ambient temperature. The flow rate of the mobile phase was adjusted to 1.0mL/min and the injection volume was 10μL. Detection was performed by photodiode array detector at a wavelength of 210nm and the chromatographic runtime was 6 minutes for the analysis. The reliability and analytical performance of the proposed method, including linearity, range, precision, accuracy, detection and quantitation limits, were statistically validated. The proposed method can be useful in the quality control of combination drug products